Beijing Chest Hospital, Capital Medical University
11
5
5
1
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 11 trials
100.0%
+13.5% vs industry average
27%
3 trials in Phase 3/4
0%
0 of 1 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
A Phase II Single-arm Clinical Study in the Treatment of Locally Advanced Esophageal Cancer After Failed Neoadjuvant Chemoimmunotherapy
Role: collaborator
Microbial Colonization Distribution and Adaptive Evolution of Lower Respiratory Tract in Bronchiectasis Patients.
Role: collaborator
Short-term Bactericidal Effect of Contezolid in MAC-PD
Role: collaborator
Clinical Trial to Evaluate the Efficacy and Safety of EEC for the Diagnosis of Mycobacterium Tuberculosis Infection in People Aged 3 Years and Above
Role: collaborator
Study of Iparomlimab and Tuvonralimab Plus Chemotherapy in Malignant Mesothelioma
Role: collaborator
Ultra-Short Regimen for Elderly DS-TB
Role: collaborator
Adebrelimab Plus Chemo and Recaticimab in Perioperative Treatment of Resectable NSCLC
Role: lead
Establishment of Cohort Under the Guidance of the Pathogenesis of Cancer Toxin in Traditional Chinese Medicine
Role: collaborator
PD-L1/PD-1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone for the Neoadjuvant Treatment of Limited-stage SCLC
Role: lead
Clinical Trial to Explore the Skin Test Dosage of EEC in People Aged 18 to 65 Years Old and the Safety and Preliminary Efficacy in People Aged 3 to 75 Years Old.
Role: collaborator
Phase I Clinical Trial to Evaluate the Safety of Recombinant Mycobacterium Tuberculosis Fusion Protein (EEC) in Healthy Adults Aged 18-65 and Patients With Pulmonary Tuberculosis
Role: collaborator
All 11 trials loaded